Comparative Pharmacology
Head-to-head clinical analysis: CETAMIDE versus SOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETAMIDE versus SOXAZOLE.
CETAMIDE vs SOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.
Soxazole is a synthetic antibacterial agent that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby interfering with nucleic acid production.
500 mg orally every 6 hours; maximum 4 g per day.
500 mg orally every 6 hours for 7-14 days.
None Documented
None Documented
6-8 hours; prolonged (up to 30 hours) in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateSulfisoxazole + Gatifloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfisoxazole + Rosoxacin
"Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfisoxazole + Trovafloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfisoxazole + Nalidixic acid
Terminal elimination half-life is 8-12 hours in adults; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Primarily renal (85-90%) as unchanged drug; biliary/fecal (5-10%).
Renal excretion of unchanged drug (70-80%) and hepatic metabolism with fecal elimination (15-20%); biliary excretion accounts for minor route (<5%).
Category C
Category C
Sulfonamide antibiotic
Sulfonamide antibiotic
"Sulfisoxazole may increase the hypoglycemic activities of Nalidixic acid."